Results 1 to 10 of about 1,038,277 (244)

CH2 Domain of Mouse IgG3 Governs Antibody Oligomerization, Increases Functional Affinity to Multivalent Antigens and Enhances Hemagglutination

open access: yesFrontiers in Immunology, 2018
Mouse IgG3 is highly protective against several life-threatening bacteria. This isotype is the only one among mouse IgGs that forms non-covalent oligomers, has increased functional affinity to polyvalent antigens, and efficiently agglutinates ...
Tomasz Klaus   +2 more
doaj   +1 more source

ON THE NOTION OF SYNERGY OF MONOCLONAL ANTIBODIES AS DRUGS [PDF]

open access: yesBiotechnologia Acta, 2013
History of developing synergy between monoclonal antibodies, anti-tumor activity of monoclonal antibodies against tyrosine-kinases receptors EGFR/ErbB-1 and HER2/ErbB-2 as well as growth factor VEGF in various combinations are considered in the article ...
Michael Sela
doaj   +1 more source

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells

open access: yesFrontiers in Oncology, 2020
Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor involved in homeostatic regulation of normal cells and carcinogenesis of epithelial malignancies.
Wen-Qi Cai   +25 more
doaj   +1 more source

Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

open access: yesJournal of Biomedical Science, 2022
Background Calls for the coronavirus to be treated as an endemic illness, such as the flu, are increasing. After achieving high coverage of COVID-19 vaccination, therapeutic drugs have become important for future SARS-CoV-2 variant outbreaks.
Chen-Yi Chiang   +14 more
doaj   +1 more source

The Use of Biotechnological Drugs in Pediatrics on the Example of Monoclonal Antibodies: Clinical Pharmacology View

open access: yesПедиатрическая фармакология, 2021
The article reviews monoclonal antibodies, its structure, classifications, pharmacodynamics, pharmacokinetics, and adverse effects. There are examples for each section.
Alexey S. Kolbin   +1 more
doaj   +1 more source

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma

open access: yesLeukemia Research Reports, 2022
The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody in combination with chemotherapy or as a single agent in the treatment of indolent non-Hodgkin lymphomas has paved the way for development of various forms of
Suheil Albert Atallah-Yunes   +1 more
doaj   +1 more source

Characterization of protective and non-protective surface membrane carbohydrate epitopes of Schistosoma mansoni

open access: yesMemorias do Instituto Oswaldo Cruz, 1987
We have produced a number of monoclonal antibodies, protective and non-protective, which recognize a complex of schistosomula antigens, including the 38 kDa antigen. Eight different protective and non-protective monoclonal antibodies, varying in isotypes,
Albert I. Ko, Donald A. Harn
doaj   +1 more source

Washing with alkaline solutions in protein A purification improves physicochemical properties of monoclonal antibodies

open access: yesScientific Reports, 2021
Protein A affinity chromatography has been widely used for both laboratory scale purification and commercial manufacturing of monoclonal antibodies and Fc-fusion proteins. Protein A purification is specific and efficient.
Yuichi Imura   +7 more
doaj   +1 more source

Monoclonal antibodies: their place in applied medicine and their role in the newest infectious disease – history, present, and future. Literature review [PDF]

open access: yesPharmacia
Monoclonal antibodies (mAbs) are immunoglobulins with practically absolute specificity (monospecificity) for a particular antigen (epitope). Over the past three decades, monoclonal antibodies have undergone a remarkable transformation, evolving from ...
Petar Yordanov Atanasov   +11 more
doaj   +3 more sources

38227 Specific and highly potent human monoclonal antibodies against SARS-CoV-2

open access: yesJournal of Clinical and Translational Science, 2021
IMPACT: We devised a new method to produce highly potent SARS-CoV2-specific that can be used to treat severely ill patients with Covid-19. OBJECTIVES/GOALS: Neutralizing antibodies against SARS-CoV-2 are thought to offer the most immediate and effective ...
Mayara Garcia de Mattos Barbosa   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy